Drugmaker Natco Pharma’s June quarter consolidated net profit slumped 57% year-on-year (YoY) to ₹206.5 crore on the back of lower sales of generic cancer drug Lenalidomide.

The profit came on a nearly 43% YoY dip in total revenue to ₹794.4 crore, largely attributable to lower sales earnings from Lenalidomide — generic of once blockbuster cancer drug Revlimid. Growth in the base business helped partially offset the drop, the company said on Friday.

Natco Pharma shares ended 5.23% lower on the BSE at ₹902.40 apiece.

International formulations, including profit share and subsidiaries, declined to ₹477.1 crore against ₹1,120.9 crore the previous year period, showed the segmental revenue numbers of the company for the quarter.

Revenues from active pharmaceutical ingredients (API) stood at ₹66.7 crore compared to ₹52.6 crore the corresponding period of FY26); domestic pharmaceutical formulations ₹136.4 crore (₹107 crore); and crop health sciences ₹40.8 crore (₹34.7 crore) .

However, other operating and non-operating income declined marginally to ₹73.4 crore (₹75.4 crore).

Revenue of associate company Adcock Ingram Holdings, South Africa, was ₹1,582.8 crore and profit after tax ₹242.2 crore. Natco’s share of profit (based on the 35.75% holding as on June 30) stood at ₹84.3 crore. In July, Natco announced the acquisition of an additional 13.25% stake in Adcock Ingram Holding taking it stake to 49%.

₹1.5 interim dividend

Natco Board has declared an interim dividend of ₹1.5 per equity share of ₹2 each. The record date has been fixed as August 20 and the payment of the interim dividend will start from August 26.

Hyderabad-based Indian multinational pharmaceutical and biotechnology company Natco Pharma’s shares were in the spotlight on Monday after it received tentative approval from the U.S. Food and Drug Administration (FDA) for Olaparib, 100 mg, and 150 mg, which are bioequivalent to AstraZeneca Pharmaceuticals’ referenced drug Lynparza used in the treatment of certain types of cancer.

The shares of the generic drugmaker touched more than 4% intra-day before ending the day less than 1% higher at Rs.950.55 each.

On Saturday, announcing the U.S. FDA approval, Natco Pharma said it would be manufacturing Olaparib tablets while its partner Alembic Pharmaceuticals would be distributing the product in the U.S. Olaparib tablets had estimated sales of around $1.4 billion in the U.S. for 12 months ending March 2026 as per industry sales data. The Para IV litigation, a statutory mechanism to resolve drug patent disputes, is on-going, it said.